MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.

Florida adds neglected FOIA requests to amended lawsuit against FDA over drug imports

The state of Florida on Monday again took a swing at the FDA, alleging in an amended lawsuit filed in a Florida district court that

August 17, 2023

Clinical trials becoming more inclusive across race and ethnicity, new data shows

Clinical trials and medical research have been historically lacking in diversity among all groups.

February 5, 2024

Henry Ford Health and MSU continue groundbreaking medical research initiative

Michiganders will continue to have the opportunity to advance medical research aimed at advancing individualized health care through a renewed award to Henry Ford Health

January 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.